(RTTNews) - Eye health company Bausch + Lomb Corp. (BLCO) announced Tuesday the U.S. commercial launch of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms ...

MIEBO is the First and Only Prescription Eye Drop that Directly Targets Tear Evaporation, the Leading Cause of Dry Eye Disease DED affects more than 38 million Americans, with approximately nine in 10 ...

After closing on its IPO last May in anticipation of its upcoming spinout from Bausch Health, eyecare specialist Bausch + Lomb has won its first prescription drug approval from the FDA. Thursday, the ...

Bausch + Lomb has teamed up with American sportscaster Erin Andrews to promote its dry eye disease treatment, launching the “Miebo ohh yeah” campaign to spread the word about the condition and drug.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S.

Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb has announced the U.S. commercial launch of Miebo, a perfluorohexyloctane ophthalmic solution ...

MIEBO is the First and Only Prescription Eye Drop that Directly Targets Tear Evaporation, the Leading Cause of Dry Eye Disease VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading ...

MIEBO is the First and Only Prescription Eye Drop that Directly Targets Tear Evaporation, the Leading Cause of Dry Eye Disease Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health ...